ZYUS Life Sciences Corporation Announces Assumption and Amendment of Promissory Note
ZYUS Life Sciences Corporation (the "Company") (TSX-V: ZYUS), a Canadian-based life sciences company focused on the ...
The Manila Times21 分钟
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the ...
FILSPARI REMS: Due to the risk of hepatotoxicity and embryo-fetal toxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Prescribers, patients, and pharmacies must ...